8legs: American society of clinical oncology meeting

Your Followed Topics

#1 out of 395.71%

New cancer jab amivantamab induced tumour shrinkage or disappearance in 43 of 102 patients across an 11-country trial.
The three-action jab targets EGFR and MET and boosts immune attack on tumours.
Patients with head and neck cancers benefited, including those who had not HPV-related disease.
Median overall survival after starting treatment was 12.5 months amid challenging disease.
The jab is administered under the skin, offering quicker, outpatient treatment.
The study spanned 11 countries and involved patients with advanced disease after other therapies failed.
Johnson & Johnson developed amivantamab, now under evaluation in around 60 clinical trials.
Martin Harrington of ICR called the responses unprecedented for resistant cancers.
Researchers plan to expand the approach to other cancer types with ongoing trials.
Trial results will be presented at ASCO, the world’s largest cancer conference.

Vote 0

#2 out of 3

The trial enrolled 142,942 NHS patients aged 50 to 77 with no cancer symptoms and followed them for three years.
Results showed the primary endpoint—reduction in late-stage cancers—was not met.
Some secondary findings suggested a potential decline in stage four cancers, yet experts urged caution.
Grail described the findings as encouraging for some measures, while others remain uncertain.
Independent experts cautioned that the main outcome was not met and results should be interpreted carefully.
The trial was conducted within the NHS and presented at the ASCO annual meeting in Chicago.
Experts emphasized that mortality outcomes will be informative in a couple of years.
NHS England and NHS Improvement were involved in conducting the trial and evaluating its implications.
The Galleri test is produced by Grail, which defended the study's potential despite the primary endpoint result.
NHS leaders await detailed data to guide future decisions about population screening.
Overall, the study did not demonstrate a clear population-level benefit for Galleri within the trial period.

Vote 0

#3 out of 3

A new daily pill, daraxonrasib, targets the KRAS gene and shows promising survival in pancreatic cancer patients.
In early Phase 1/2 data, overall survival for patients on daraxonrasib reached about 13.2 months, near doubling standard care.
About one-third of patients with the KRAS G12 mutation showed an objective tumor response to the drug.
A 30% incidence of severe side effects, including rash and GI issues, accompanies daraxonrasib.
FDA fast-tracked limited approval raised access and equity questions for patients and providers.
Cost and affordability remain unresolved as doctors anticipate insurance coverage challenges.
Researchers aim to broaden use earlier in treatment and explore combinations with immunotherapy or surgery.
Revolution Medicines plans a full Phase 3 readout at the ASCO annual meeting to shape future approvals.
Experts see potential for the drug to alter the standard of care for PDAC if earlier use proves beneficial.

Vote 0

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.